FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD, PAD FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD, PAD

The rivaroxaban/aspirin combination is for the prevention of thrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Alert Source Type: news